Levofloxacin Cooper (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes that control DNA supercoiling and replication. By preventing these enzymes from functioning, the drug stops bacterial DNA synthesis, leading to cell death. This mechanism gives levofloxacin a bactericidal effect against many Gram‑negative and Gram‑positive organisms.

The dosage of Levofloxacin Cooper is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and local resistance patterns. Healthcare professionals select the appropriate dose and infusion rate; patients should follow the prescriber's instructions without alteration.

Levofloxacin is classified as pregnancy category unknown in many regions, and animal studies have shown potential risks to the fetus. It is generally avoided in pregnancy and lactation unless the benefits outweigh the risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Levofloxacin offers once‑daily dosing for many indications and has a broad spectrum that includes both Gram‑negative and Gram‑positive bacteria, often providing higher potency against Streptococcus pneumoniae compared with ciprofloxacin. However, safety considerations such as tendon toxicity and QT prolongation are similar across the class, so selection depends on the infection, susceptibility data, and patient risk factors.

Levofloxacin Cooper should be stored at temperatures below 25 °C, protected from moisture, light, and physical shock. Keep the product in its original packaging until use, and avoid exposing the solution to extreme temperatures or direct sunlight to maintain stability and potency.

Levofloxacin Cooper is supplied as an intravenous solution for infusion. It is typically administered over a period of 30 to 60 minutes, depending on the prescribed dose and patient tolerance. Administration should be performed by qualified healthcare personnel in a clinical setting, following aseptic technique and manufacturer instructions.

Serious adverse events include tendon rupture (especially the Achilles tendon), QT interval prolongation leading to arrhythmias, severe Clostridioides difficile‑associated diarrhea, hypersensitivity reactions such as anaphylaxis, and central nervous system effects like seizures. Patients should be monitored for these events, and therapy should be stopped immediately if they occur.

Levofloxacin Cooper is contraindicated in individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. It should also be avoided in patients with a history of tendon disorders related to fluoroquinolone use, uncontrolled QT prolongation, or those for whom safer alternative antibiotics are available.